On the public citation graph
How Excluding Some Benefits from Value Assessment of New Medicines Impacts Innovation
0 signed · 29 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/hec.1538openalex-extracted
Drug development costs when financial risk is measured using the Fama–French three‐factor model
inferredcites →https://doi.org/10.1002/hec.3086openalex-extracted
The Influence of Cost‐Effectiveness and Other Factors on Nice Decisions
inferredcites →https://doi.org/10.1002/hec.864openalex-extracted
Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysis
inferredcites →https://doi.org/10.1016/0167-6296(94)90010-8openalex-extracted
Returns to R&D on new drug introductions in the 1980s
inferredcites →https://doi.org/10.1016/0304-405x(79)90015-1openalex-extracted
Option pricing: A simplified approach
inferredcites →https://doi.org/10.1016/0304-405x(93)90023-5openalex-extracted
Common risk factors in the returns on stocks and bonds
inferredcites →https://doi.org/10.1016/j.clinthera.2013.04.004openalex-extracted
Innovating by Developing New Uses of Already-Approved Drugs: Trends in the Marketing Approval of Supplemental Indications
inferredcites →https://doi.org/10.1016/j.jhealeco.2012.10.002openalex-extracted
Endogenous cost-effectiveness analysis and health care technology adoption
inferredcites →https://doi.org/10.1016/s0167-6296(00)00048-5openalex-extracted
Incorporating option values into the economic evaluation of health care technologies
inferredcites →https://doi.org/10.1016/s0167-6296(02)00126-1openalex-extracted
The price of innovation: new estimates of drug development costs
inferredcites →https://doi.org/10.1016/s0304-405x(96)00896-3openalex-extracted
Industry costs of equity
inferredcites →https://doi.org/10.1023/a:1008283011490openalex-extracted
Binomial Option Pricing with Skewed Asset Returns
inferredcites →https://doi.org/10.1038/nrd3405openalex-extracted
The productivity crisis in pharmaceutical R&D
inferredcites →https://doi.org/10.1080/13571516.2011.584428openalex-extracted
Real Option Value and Path Dependence in Oncology Innovation
inferredcites →https://doi.org/10.1080/13696998.2017.1302453openalex-extracted
The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib
inferredcites →https://doi.org/10.1111/j.1540-6261.1997.tb03808.xopenalex-extracted
On Persistence in Mutual Fund Performance
inferredcites →https://doi.org/10.1111/j.1875-595x.2011.00075.xopenalex-extracted
Collaboration between dental faculties and National Dental Associations (NDAs) within the World Dental Federation-European Regional Organization zone: an NDAs perspective
inferredcites →https://doi.org/10.1177/0272989x10371134openalex-extracted
Does Medicare Have an Implicit Cost-Effectiveness Threshold?
inferredcites →https://doi.org/10.1200/jco.2016.34.15_suppl.6610openalex-extracted
The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib.
inferredcites →https://doi.org/10.1200/jop.2011.000300openalex-extracted
Health Technology Assessment and Private Payers' Coverage of Personalized Medicine
inferredcites →https://doi.org/10.1287/mnsc.36.7.804openalex-extracted
A New Look at the Returns and Risks to Pharmaceutical R&D
inferredcites →https://doi.org/10.1377/hlthaff.2011.1300openalex-extracted
How Cancer Patients Value Hope And The Implications For Cost-Effectiveness Assessments Of High-Cost Cancer Therapies
inferredcites →https://doi.org/10.1377/hlthaff.2014.1123openalex-extracted
Medicare Is Scrutinizing Evidence More Tightly For National Coverage Determinations
inferredcites →https://doi.org/10.2165/00019053-200220003-00002openalex-extracted
Returns on Research and Development for 1990s New Drug Introductions
inferredcites →https://doi.org/10.2202/1558-9544.1005openalex-extracted
Who Benefits from New Medical Technologies? Estimates of Consumer and Producer Surpluses for HIV/AIDS Drugs
inferredcites →https://doi.org/10.3390/ijerph7041835openalex-extracted
Health Economic Assessment: Cost-Effectiveness Thresholds and Other Decision Criteria
inferredcites →https://doi.org/10.4236/jmf.2012.21013openalex-extracted
A Skewness-Adjusted Binomial Model for Pricing Futures Options—The Importance of the Mean and Carrying-Cost Parameters
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.